Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
We investigated the impact of long-term levothyroxine (LT4) treatment on bone mineral density (BMD) and bone turnover markers (BTMs) in premenopausal women with differentiated thyroid cancer (DTC) after thyroidectomy. 65 premenopausal women who received LT4 therapy at least 1 year after thyroidectomy for DTC and 50 premenopausal women without thyroid diseases were enrolled in this study. We measured the T-scores of lumbar and hip BMD, Serum free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), intact parathyroid hormone (iPTH), N-terminal propeptide of type 1 N procollagen (P1NP), C-terminal telopeptide of type 1 collagen (CTX-1), calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) in all participants. In DTC subjects, serum TSH levels was lower, serum FT4, P1NP, CTX-1 and ALP levels were higher compared with controls. The prevalence of osteopenia was higher in DTC subjects than in controls. Multivariate logistic regression analysis showed that serum TSH levels were negatively associated with CTX-1 and ALP. We found high prevalence of osteopenia among premenopausal women who received long-term LT4 therapy for DTC after thyroidectomy. Long-term TSH suppression therapy was an significant risk factor for decreased bone strength mainly by increasing bone turnover.